Berkshire requires a 25–50% discount to intrinsic value before buying.
Buffett Quality Checklist
✓ROE >15% consistently (≥7 of last 10 years)
✓Free cash flow positive (≥8 of last 10 years)
✗Conservative leverage — Debt/Equity below 1
✗Revenue growing at CAGR >5%
✓EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
Year▲
Revenue▲
Net Income▲
FCF▲
Owner Earnings▲
ROE▲
Net Margin▲
LT Debt▲
Cash▲
2016
$15.2B
$2.4B
$2.5B
$2.3B
—
16.1%
$6.5B
$1.3B
2017
$15.5B
$2.0B
$2.5B
$1.9B
—
13.1%
$6.6B
$1.5B
2018
$15.5B
$2.4B
$2.6B
$2.5B
—
15.4%
$6.4B
$726.0M
2019
$15.7B
$2.4B
$2.8B
$2.6B
2023.1%
15.1%
$7.3B
$883.0M
2020
$16.5B
$2.7B
$3.3B
$2.8B
362.7%
16.4%
$7.3B
$888.0M
2021
$17.4B
$2.2B
$2.8B
$2.2B
355.7%
12.4%
$7.2B
$832.0M
2022
$18.0B
$1.8B
$1.9B
$1.6B
445.1%
9.9%
$8.7B
$775.0M
2023
$19.5B
$2.3B
—
—
377.7%
11.8%
$8.2B
$966.0M
2024
$20.1B
$2.9B
—
—
1362.7%
14.4%
$7.0B
$1.1B
2025
$20.4B
$2.1B
—
—
3948.1%
10.5%
$7.8B
$1.3B
Warren & Charlie
Buffett / Munger — quality, moat & valuation
COLGATE PALMOLIVE CO (CL) — Investment Memo
🐂 The Bull Case (Warren's voice)
The Ultimate Toll Bridge: Colgate doesn't sell a luxury; it sells a daily ritual. The moat isn't technical superiority—it's psychological ubiquity. When a consumer reaches for toothpaste in 200 countries, the friction of switching brands for a few cents is higher than the perceived benefit of the alternative.
Inflation Hedge: Household staples possess the "hidden" pricing power of invisibility. A $0.25 price hike on a tube of toothpaste is rarely noticed by the consumer but drops straight to the bottom line when scaled across billions of units.
Predictability: The revenue stream is a heartbeat—steady, rhythmic, and largely indifferent to the GDP of the quarter. It is a "sleep-well-at-night" business if the price is right.
Attractive Entry: To move the needle for Berkshire, we need this to be a "cigar butt" with a few good puffs left, or a wonderful business at a fair price. Given the current DCF, it becomes genuinely attractive only if it trades like a commodity company rather than a consumer darling.
🐻 The Bear Case (Charlie inverts)
“Show me where I'll die and I won't go there.”
The Commodity Trap: The most lethal scenario is the normalization of private labels. If the consumer decides that "Store Brand Toothpaste" is functionally identical to Colgate, the brand premium evaporates. We aren't fighting a competitor; we are fighting the realization that the product is a commodity.
The Margin Death Spiral: The numbers are screaming. A drop from 16.1% to 10.5% operating margins isn't a "cycle"—it's a structural leak. If management is using "productivity programs" (cost-cutting) to mask an inability to raise prices, the business is a melting ice cube.
The Distribution Pivot: Colgate's moat is "shelf space." If the primary point of purchase shifts decisively toward direct-to-consumer (DTC) or algorithmic subscriptions, the "inertia" of the supermarket aisle vanishes.
Most Likely Failure: Margin erosion. This is already happening. The timeframe is immediate and ongoing. They are spending more to make less.
💰 Valuation & Margin of Safety
The DCF suggests the market is pricing in a fantasy of growth that the financials do not support.
Intrinsic value estimate: $34.16 per share
25% margin of safety entry: $25.62(conservative)
50% margin of safety entry: $17.08(Buffett's ideal)
Current Status: Grossly expensive. Based on the DCF of $34.16, the stock is trading at a massive premium to its actual cash-generating power. We are being asked to pay for a growth story that the 2.4% CAGR flatly denies.
Verdict: PASS
The price is wildly disconnected from the intrinsic value of $34.16. We cannot ignore the steady erosion of operating margins from 16.1% to 10.5%. The moat is narrowing, and the price is soaring; we move on.
Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management
Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.